Antibiotics Causing Bone Marrow Suppression

1. Chloramphenicol - The Most Important

A. Dose-Dependent (Reversible) Suppression

• Occurs when plasma concentrations reach ≥25 μg/mL, or with prolonged/repeated use
• Caused by inhibition of mitochondrial protein synthesis in erythroid precursors, which impairs iron incorporation into heme
• Manifests as anemia, leukopenia, or thrombocytopenia
• Reversible upon dose reduction or discontinuation
• May progress to aplasia if treatment is continued

B. Idiosyncratic Aplastic Anemia (Irreversible)

• Occurs in approximately 1 in 30,000 courses of therapy - rare but potentially fatal
• Not dose-related; most cases develop WITHOUT prior dose-related marrow suppression
• Mechanism: intestinal bacteria convert the nitro group of chloramphenicol to a toxic intermediate that directly damages stem cells
• Results in pancytopenia; fatality rate is high when aplasia is complete
• Survivors have an increased incidence of acute leukemia
• Composition of dyscrasias: ~70% aplastic anemia; remainder is hypoplastic anemia, agranulocytosis, and thrombocytopenia
• More common with prolonged therapy and repeated exposures

Source: Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 1206

2. Linezolid (and Oxazolidinones)

• Causes reversible myelosuppression: anemia, leukopenia, pancytopenia, and most commonly thrombocytopenia
• Thrombocytopenia onset is typically between 7-10 days after starting therapy
• Risk is significantly higher with treatment courses >2 weeks
• Mechanism: inhibition of mitochondrial protein synthesis (same target as chloramphenicol's reversible effect), leading to impaired hematopoiesis
• All effects are reversible on discontinuation
• Monitoring: Weekly CBC is mandatory for therapy lasting ≥2 weeks; also monitor patients with baseline thrombocytopenia or coagulopathy
• Tedizolid (next-generation oxazolidinone) may have a lower propensity for myelosuppression based on early data

Source: Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 1206; Washington Manual of Medical Therapeutics

3. Trimethoprim-Sulfamethoxazole (TMP/SMX)

• Hematologic toxicity is one of the most common adverse reactions (alongside nausea, rash, hyperkalemia)
• Trimethoprim inhibits dihydrofolate reductase - in high doses or immunocompromised patients, this leads to folate deficiency-like effects on hematopoiesis (megaloblastic changes, neutropenia)
• Sulfonamides can cause agranulocytosis, aplastic anemia (rare), and hemolytic anemia (especially in G6PD-deficient individuals) by immune-mediated and direct toxic mechanisms
• Aplastic anemia with TMP/SMX is rare but documented, particularly with long-term prophylactic use (e.g., in HIV patients)
• Patients on long-term TMP/SMX should have monthly hematologic monitoring

Source: Lippincott Illustrated Reviews Pharmacology; Fitzpatrick's Dermatology; Tintinalli's Emergency Medicine

4. Beta-Lactams (Penicillins, Cephalosporins)

• Immune-mediated drug-induced neutropenia (hapten mechanism): penicillin and sulfa drugs act as haptens, triggering immune destruction of neutrophil precursors
• High-dose, prolonged IV penicillin (e.g., for infective endocarditis) is the most recognized scenario - neutropenia resolves after stopping the drug
• Also listed as a cause of aplastic anemia in neonatal neutropenia tables (Fishman's Pulmonary Diseases)
• Overall incidence is low but clinically significant in settings requiring prolonged therapy

Summary Table

Key Clinical Points

• Chloramphenicol is now rarely used systemically (mainly in resource-limited settings for typhoid fever and meningitis) precisely because of this toxicity profile
• Linezolid myelosuppression is the primary dose-limiting adverse effect in prolonged use (e.g., MDR-TB treatment, chronic osteomyelitis)
• The common mnemonic for aplastic anemia-causing drugs includes Chloramphenicol, Sulfonamides, and other agents (NSAIDs, gold, antithyroid drugs)
• In all cases of antibiotic-induced bone marrow suppression, the first step is discontinuation of the offending agent; severe aplastic anemia may require bone marrow transplant or immunosuppression (ATG + cyclosporine)